Publication: ECONOMICAL MULTIPLE-SITE INTRADERMAL IMMUNISATION WITH HUMAN DIPLOID-CELL-STRAIN VACCINE IS EFFECTIVE FOR POST-EXPOSURE RABIES PROPHYLAXIS
Issued Date
1985-05-11
Resource Type
ISSN
01406736
Other identifier(s)
2-s2.0-0021885882
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
The Lancet. Vol.325, No.8437 (1985), 1059-1062
Suggested Citation
M. J. Warrell, D. A. Warrell, K. G. Nicholson, Pravan Suntharasamai, Pornthep Chanthavanich, Chaisin Viravan, Abha Sinhaseni, M. K. Chiewbambroongkiat, X. Pouradier-Duteil, Rod Phanfung, C. Xueref, Dusit Udomsakdi ECONOMICAL MULTIPLE-SITE INTRADERMAL IMMUNISATION WITH HUMAN DIPLOID-CELL-STRAIN VACCINE IS EFFECTIVE FOR POST-EXPOSURE RABIES PROPHYLAXIS. The Lancet. Vol.325, No.8437 (1985), 1059-1062. doi:10.1016/S0140-6736(85)92367-0 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/30868
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
ECONOMICAL MULTIPLE-SITE INTRADERMAL IMMUNISATION WITH HUMAN DIPLOID-CELL-STRAIN VACCINE IS EFFECTIVE FOR POST-EXPOSURE RABIES PROPHYLAXIS
Abstract
An economical post-exposure regimen of Mérieux human diploid-cell-strain vaccine (HDCSV) was compared with Semple vaccine (SV), the most widely used vaccine in Asia. 155 patients bitten by animals proved to be rabid received either conventional courses of SV (34 severe and 43 mild cases) or HDCSV, 0·1 ml intradermally, at eight sites on day 0, at four sites on day7, and at one site on days 28 and 91 (36 severe and 42 mild cases). All severely bitten patients were given equine anti-rabies serum (EARS), 80 IU/kg on day 0. There were no deaths from rabies in either group. Follow-up was 97·5% at 1 year and 93% at 2 years. 88% of patients given HDCSV alone had detectable neutralising antibody on day 7 in contrast to 2% given SV alone. Antibody persisted until 1 year in all sera tested from HDCSV patients in contrast to only 48% of SV sera. The high dose of EARS resulted in pronounced suppression of response to HDCSV. There were no serious systemic side-effects but local side-effects were significantly more common in the SV group. The multiple-site intradermal HDCSV regimen was at least as effective as SV. The amount of HDCSV used was 30% of the conventional dose. © 1985.